IBN Sina Scientific Bureau Pharmaceutical Import Profile — Iraq (DGFT 2022–2026)

Name: IBN Sina Scientific Bureau Pharmaceutical Import Records from India — 5 Products, $3.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

IBN Sina Scientific Bureau — Pharmaceutical Importer Profile (2026) | 5 Products, $3.8M Trade | TransData Nexus

IBN Sina Scientific Bureau

Pharmaceutical Importer · Iraq · Respiratory & OTC Focus · $3.8M Total Trade · DGFT Verified

IBN Sina Scientific Bureau is a pharmaceutical importer based in Iraq with a total trade value of $3.8M across 5 products in 4 therapeutic categories. Based on 127 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. IBN Sina Scientific Bureau sources from 2 verified Indian suppliers, with Brawn Laboratories Limited accounting for 98.2% of imports.

IBN Sina Scientific Bureau — Import Portfolio & Supplier Network

IBN Sina Scientific Bureau import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to IBN Sina Scientific Bureau?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Brawn Laboratories Limited	$7.0M	314	98.2%
Glenmark Pharmaceuticals Limited	$129.8K	3	1.8%

IBN Sina Scientific Bureau sources from 2 verified Indian suppliers across .

What Formulations Does IBN Sina Scientific Bureau Import?

Formulation	Value	Ships
Each hard gelatin capsule contains :dried ferrous sulphate BP 150MG eq. to ferrous iron 48.75MG folic acid BP	$398.1K	15
Amikacin sulphate injection 500MG/2ML vial (clear,colourless to pale yellow solution filled in clear glass sealed	$181.6K	6
Each hard gelatin capsule contains : dried ferrous sulphate BP 150MG eq. to ferrous iron 48.75MG folic acid BP	$156.8K	6
Each uncoated TAB conts:paracetamol BP 500MG caffeine(as anhydrous)BP 25MG phenylephrine hydrochloride BP	$148.8K	12
Each uncoated TAB cont:paracetamol BP 500MG caffeine (as anhydrous)BP 25MG phenylephrine hydrochloride BP	$140.0K	3
Mefenamic acid capsules BP 250MG (mefstan)bt# bnc0124032-37bnc0124040-42bnc0124045d/m01/24d/e-12/26nos	$115.6K	3
Each hard gelatin capsule conts:lansoprazole USP 30MG (as enteric coated pellets)-lanax 30,bn:bnc0324005 to	$105.7K	3
Azithromycin oral suspension 200MG/5ML-30ML bottle (pinkish white granular powder forming pink coloured suspension on	$100.0K	2
Paracetamol , phenylephrine hydrochloride and guaifenesin tablets Each film coated tablet contains: paracetamol	$100.0K	2
Each uncoated tablet contains : loratadine USP 10MG,bt# bnt0424029-32,d/m-04/24	$95.6K	3
Each 5ML conts:chlorpheniramine maleateusp 1MG,glyceryl guaiacolate 50MG ( guaifenesin USP ), phenylephrine	$89.9K	6
Each 5ML conts:chlorpheniramine maleateusp 1MG,glyceryl gualacolate 50MG ( guaifenesin USP ), phenylephrine	$89.8K	6
Each uncoated tablet contains olanzapineusp 10MG - bt: bnt0424024-026, d/m: 04-24, d/e	$89.3K	3
Each hard gelatin capsule conts:lansoprazole USP 15MG (as enteric coated pellets)-l-15,bn:bnc0324001 to 04	$88.7K	3
Contains :sodium chloride BP 0.9% w/v inan isotonic solution using purified water BP q.s.(preservative	$86.2K	3

IBN Sina Scientific Bureau imports 153 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Phenylephrine	Respiratory & OTC	$1.1M	37	1.2%	18
2	Albendazole	Antimalarial & Antiparasitic	$998.7K	38	1.4%	9
3	Guaifenesin	Respiratory & OTC	$758.9K	22	2.8%	6
4	Folic	Nutritional Supplements	$633.1K	24	1.1%	9
5	Amikacin	Advanced Antibiotics	$300.0K	6	1.4%	9

IBN Sina Scientific Bureau imports 5 pharmaceutical products across 4 categories into Iraq totaling $3.8M.

IBN Sina Scientific Bureau — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

IBN Sina Scientific Bureau is a prominent pharmaceutical importer and distributor based in Baghdad, Iraq. Established with a mission to provide quality-assured healthcare solutions, the company has become a leading entity in the medical care industry within Iraq. IBN Sina imports a diverse range of pharmaceutical products from global partners, ensuring their availability to clients across the country.

The company's vision is to deliver outcome-based healthcare and well-being services to the community, collaborating with clients, staff, and partners. Its mission focuses on adding exceptional value through the distribution of innovative medical products and services for the benefit of the medical community and human health worldwide.

2Distribution Network

While specific details about IBN Sina Scientific Bureau's warehouse locations and logistics capabilities are not publicly disclosed, the company emphasizes its ability to fulfill urgent and bulk requirements efficiently. This suggests a well-established distribution network capable of covering all Iraqi governorates, including Kurdistan.

3Industry Role

IBN Sina Scientific Bureau operates as a primary wholesaler and distributor in Iraq's pharmaceutical supply chain. By importing a wide array of pharmaceutical products and ensuring their distribution across the country, the company plays a crucial role in supplying medications to hospitals, clinics, pharmacies, and healthcare professionals.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — IBN Sina Scientific Bureau

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy reveals a significant concentration on a limited number of suppliers. Over the past four years, IBN Sina Scientific Bureau has imported finished pharmaceutical formulations exclusively from two Indian suppliers: Brawn Laboratories Limited and Glenmark Pharmaceuticals Limited. Brawn Laboratories Limited has been the dominant supplier, accounting for approximately 98.2% of the total shipments, while Glenmark Pharmaceuticals Limited contributed about 1.8%.

This sourcing pattern indicates a strategic choice to maintain stable and long-term relationships with these suppliers. The high volume of imports from Brawn Laboratories Limited suggests a strong partnership, likely due to consistent product quality, reliability, and favorable pricing. The limited number of suppliers may also reflect a focused approach to ensure supply chain efficiency and manageability.

2Supply Chain Resilience

The resilience of IBN Sina Scientific Bureau's supply chain appears robust, given the long-standing relationship with Brawn Laboratories Limited, which has been the exclusive agent for over 15 years. This enduring partnership indicates a stable and reliable supply of pharmaceutical products. However, the limited number of suppliers could pose risks in terms of supply chain diversification. To mitigate potential disruptions, it would be prudent for the company to consider expanding its supplier base and exploring alternative sources to enhance supply chain resilience.

Importing Pharmaceuticals into Iraq — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Iraq

1Regulatory Authority & Framework

In Iraq, the Ministry of Health is the primary regulatory authority overseeing pharmaceutical imports. Pharmaceutical companies and products must be registered with the Technical Affairs Directorate. Market authorization holders are responsible for product quality and recalls, with the regulator's ability to enforce quality pharmacovigilance being limited. The Ministry of Health mandates the right to carry out inspections to ensure good manufacturing practice (GMP) compliance if deemed necessary.

2Import Licensing & GMP

Import licensing requirements in Iraq stipulate that pharmaceutical products must be registered with the Ministry of Health. Registration is valid for five years for imported products. Manufacturers of both prescription-only drugs and over-the-counter (OTC) medicines are required to register products, although the latter does not require bioavailability data or bioequivalence studies. The Ministry of Health has the authority to inspect facilities to ensure compliance with GMP standards.

3Quality & Labeling

IBN Sina Scientific Bureau — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

IBN Sina Scientific Bureau's focus on importing products in the Respiratory & OTC, Antimalarial & Antiparasitic, and Nutritional Supplements categories aligns with prevalent health concerns in Iraq. The high import values in these categories indicate substantial market demand, driven by factors such as respiratory illnesses, parasitic infections, and nutritional deficiencies. By concentrating on these therapeutic areas, the company addresses critical healthcare needs and positions itself as a key supplier in these segments.

2Sourcing Profile

The company's sourcing strategy emphasizes generic drug formulations, particularly in the Respiratory & OTC, Antimalarial & Antiparasitic, and Nutritional Supplements categories. India's established pharmaceutical industry, known for its compliance with international quality standards and competitive pricing, makes it an attractive sourcing destination. This approach enables IBN Sina Scientific Bureau to offer a diverse product portfolio that meets the therapeutic needs of the Iraqi market.

3Market Positioning

Based on its product mix, IBN Sina Scientific Bureau serves multiple segments of the Iraqi pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive distribution network ensures that its products reach a wide range of healthcare providers and consumers, reinforcing its position as a comprehensive supplier in the market.

Seller's Guide — How to Become a Supplier to IBN Sina Scientific Bureau

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with IBN Sina Scientific Bureau. The company's concentrated sourcing pattern suggests potential gaps in its current supply chain that could be addressed by introducing alternative suppliers. Indian exporters can leverage this opportunity by offering high-quality products, ensuring regulatory compliance, and providing competitive pricing to meet the demands of the Iraqi market.

2Requirements & Qualifications

Indian exporters aiming to supply IBN Sina Scientific Bureau must ensure that their products are registered with the Iraqi Ministry of Health and comply with local regulations. Manufacturers should possess valid GMP certifications recognized by the Ministry of Health. Additionally, products must meet quality standards, including batch testing, stability requirements, and labeling in Arabic. Serialization mandates must also be adhered to for traceability purposes.

3How to Approach

Frequently Asked Questions — IBN Sina Scientific Bureau

What products does IBN Sina Scientific Bureau import from India?

IBN Sina Scientific Bureau imports 5 pharmaceutical products across 4 categories. Top imports: Phenylephrine ($1.1M), Albendazole ($998.7K), Guaifenesin ($758.9K), Folic ($633.1K), Amikacin ($300.0K).

Who supplies pharmaceuticals to IBN Sina Scientific Bureau from India?

IBN Sina Scientific Bureau sources from 2 verified Indian suppliers. The primary supplier is Brawn Laboratories Limited (98.2% of imports, $7.0M).

What is IBN Sina Scientific Bureau's total pharmaceutical import value?

IBN Sina Scientific Bureau's total pharmaceutical import value from India is $3.8M, based on 127 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does IBN Sina Scientific Bureau focus on?

IBN Sina Scientific Bureau imports across 4 categories. The largest: Respiratory & OTC (48.6%), Antimalarial & Antiparasitic (26.6%), Nutritional Supplements (16.8%).

Get Full IBN Sina Scientific Bureau Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.